September 25, 2025
uniQure Announces $200 Million Proposed Public Offering
LEXINGTON, Mass. and AMSTERDAM, Sept. 24, 2025 (GLOBE NEWSWIRE) — uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing…
Pharmaceuticals, Biotechnology and Life Sciences
LEXINGTON, Mass. and AMSTERDAM, Sept. 24, 2025 (GLOBE NEWSWIRE) — uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing…
IRVINE, Calif., Sept. 24, 2025 (GLOBE NEWSWIRE) — Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that Steve Perrin, Ph.D.,…
Transaction expected to close on October 7, 2025LONDON, U.K., and RALEIGH, N.C., Sept. 24, 2025 (GLOBE NEWSWIRE) — Verona Pharma…
NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) — Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer…
NEW HAVEN, Conn., Sept. 24, 2025 (GLOBE NEWSWIRE) — Invivyd, Inc. (NASDAQ: IVVD) today announced the appointment of Paul B.…
– 86% overall survival (OS) observed at 9 months; standard of care benchmark is ~47% – – 53% progression-free survival…
Program will include an update on the Company’s lead asset, lanifibranor, ahead of anticipated Phase 3 NATiV3 topline results in…
Breakthrough Therapies and Life Sciences Leadership Take Center Stage October 1–2 in Newport BeachLOS ANGELES, Sept. 24, 2025 (GLOBE NEWSWIRE)…
H1 2025 results Activity and profitability H1 revenue: €387.8 million, down 5.4% at CER1 and on a like-for-like basis2, mainly…
RESULTS FOR THE FIRST SEMESTER OF FISCAL YEAR 2025 Revenue up 10% to €80.7 million Proprietary products account for 36%…